CHARLES OKPARA: Open Payments
NPI 1174187744 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$899 in 28 payments from 11 companies in 2025. Trend: 2023 $1,097 · 2024 $970 · 2025 $899
Food & beverage: $899
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 8 | $481 |
| Merck Sharp & Dohme LLC | 5 | $92 |
| PFIZER INC. | 4 | $86 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Gilead Sciences, Inc. | 2 | $43 |
| Syndax Pharmaceuticals, Inc. | 1 | $33 |
| Janssen Biotech, Inc. | 2 | $33 |
| Astellas Pharma US Inc | 1 | $22 |
| Novartis Pharmaceuticals Corporation | 1 | $20 |
| Exelixis Inc. | 1 | $20 |
Products named: Monjuvi, Zynyz, KEYTRUDA, Xtandi, LIBTAYO, Trodelvy, TECVAYLI, INLYTA.
Industry payments across TX — which companies pay providers there.
